H.R. 3810119th CongressReferred to the House Committee on the Judiciary.

SKIM Act

Introduced: Jun 6, 2025

Latest action: Jun 6, 2025

Latest Action

Referred to the House Committee on the Judiciary.

Congress.gov Bill Record ↗

Primary Sponsors

Cosponsors

Recorded Actions

Linked Votes

Plain-English AI Summary

What this bill means

Generated from the official bill text to make the legislation easier to understand.

Not Generated

A plain-English AI summary has not been generated for this bill yet.

Official Summary

Official legislative summary associated with this bill.

No official summary is currently available.

Primary Sponsors

Members listed as primary sponsors of this legislation.

Vince Fong

Republican • California • District 20

Primary Sponsor

Jun 6, 2025

Cosponsors

Members who joined this legislation as cosponsors.

Addison P. McDowell

Republican • North Carolina • District 6

Original Cosponsor

Jun 6, 2025

View profile →

Pete Sessions

Republican • Texas • District 17

Feb 3, 2026

View profile →

Glenn Grothman

Republican • Wisconsin • District 6

Feb 4, 2026

View profile →

James Gallagher

Republican • California • District 1

Jul 22, 2026

View profile →

Derek Schmidt

Republican • Kansas • District 2

Aug 31, 2026

View profile →

Recorded Actions

Official legislative actions recorded for this measure.

H11100Jun 6, 2025

Referred to the House Committee on the Judiciary.

Official source ↗

Intro-HJun 6, 2025

Introduced in House

Official source ↗

Linked Votes

Roll-call votes associated with this legislation.

No roll-call votes are currently linked to this bill.

Lobbying Activity

Federal lobbying disclosures that explicitly identify H.R. 3810. These records show reported lobbying involving the legislation; they do not establish that every member of Congress, sponsor, or voter was personally contacted.

PROFESSIONAL COMPOUNDING CENTERS OF AMERICA

Registrant: THORN RUN PARTNERS

1st Quarter (Jan 1 - Mar 31)

Apr 17, 2025

Reported lobbying issue

Health Issues: Issues related to drug supply chain and drug shortages. Issues related to bioidentical compounded hormones. Pharmacy: Issues related to the Drug Quality and Security Act, Compounding Pharmacy, Reimbursement, and Patient Access, animal compounding, and H.R.167 - Patient Access to Urgent-Use Pharmacy Compounding Act of 2023. H.R.3810 - Drug Origin Transparency Act of 2023. Medicare/Medicaid: Medicare Part D reimbursement of bulk substances.

Government entities reported: HOUSE OF REPRESENTATIVES SENATE

Reported filing-period amount: $30,000

This is the amount reported for the filing/reporting period and should not be interpreted as money spent lobbying this bill alone.

View official LDA filing ↗

Discussion notificationsSign in to subscribe

No comments yet. Start the conversation.